In the pharmaceutical industry, change has long been known as the only constant. But the last few years have seen the industry challenged and reshaped by drastic internal disruption and external paradigm shifts. The increasing adoption of health economics and outcomes research (HEOR) into payer decision-making means that efficacy and safety alone are no longer enough to launch even the most straightforward smallmolecule drug directly to profit.
The rise of biologicals, biomarker-targeted drugs, genespecific medications, and immune checkpoint inhibitors have provided breakthrough therapies potentially benefitting millions. At the same time, insurance to cover these drugs is chaotic in some countries, rigidly stratified by government fiat in some, and nonexistent in others.
Despite this challenging environment, the pharma industry continues to grow. Global revenue grew by 41% from 2003-2015,1 and the prescription drug market is projected to grow at a compound annual rate of 6.5% from 2016 to 2022, reaching £760 billion.2. Also, the number of stakeholders is growing, specialization is proliferating, and it is becoming increasingly difficult for anyone to have a true holistic understanding of the market in its entirety. These market transformations have necessitated changes in the nature and purpose of strategic intelligence (SI).
This paper looks at key changes in the pharma landscape through the lens of strategic intelligence, and considers how this powerful tool can help pharma stakeholders grasp the full picture of the competitive environment they intend to enter.
Deallus is a unique strategic intelligence consultancy operating across the global life sciences sector. The term strategic intelligence, common in military circles, refers to the collection, processing, analysis, and dissemination of intelligence to equip leaders to be effective strategists. Deallus’ mission is to prepare companies for the future by delivering the forward-thinking assurance they need in an uncertain and highly competitive world. The knowledge and clarity they provide aims to help life sciences companies making strategic decisions.
Pharma CIMI.CON is happy to have Deallus as lead partner in 2019. Pharma CiMi.CON 2019 is an annual international knowledge & project exchange platform bringing together 150+ competitive and market intelligence professionals for networking and exchange, to discuss key industry topics and to create new partnerships. The event, which is collocated with CiMi.CON Evolution, provides you with precise insights into new business prospects and technical strategies while offering you the chance to discuss specific roadmaps for your CI & MI projects.
Discover the next era of intelligence & insights now!
01 – 02 July | Palace Hotel Berlin, Germany